The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 11 rounds in the feed, most often at Series B and in Biotech.
Investment firmadagecapital.comRounds from 2018-10-02 to 2026-11-09
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Delix Therapeutics A clinical-stage neuroscience company pioneering the discovery and development of neuroplastogens | Series C Verified against 4 of 28 sources | $100M | 2026-11-09 | [ PART ] |
Ray Therapeutics Optogenetic therapies designed to restore functional vision for people with degenerative retinal diseases. | Series B |
| $125M |
| 2026-04-21 |
| [ PART ] |
CORXEL Pharmaceuticals Innovative therapies for cardiometabolic diseases, targeting conditions such as obesity and Type 2 Diabetes Mellitus. | Series D+ Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $287M | 2026-01-22 | [ PART ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $250M | 2026-01-12 | [ PART ] |
Ambros Therapeutics Innovative medicines for diseases with high unmet medical need, specifically targeting Complex Regional Pain Syndrome Type 1. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2025-12-16 | [ PART ] |
Kailera Therapeutics Kailera is a late clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies to provide options for people living with obesity | Series B Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $600M | 2025-10-14 | [ PART ] |
Expedition Therapeutics Expedition Therapeutics develops novel treatments for inflammatory and respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD). | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2025-10-09 | [ PART ] |
PsiQuantum PsiQuantum develops and deploys quantum computing infrastructure and software designed for enterprise, government, and research applications. | Series E Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $1.0B | 2025-09-10 | [ PART ] |
GOAT GOAT sells a wide range of sneakers, apparel, and collectibles primarily for sneaker enthusiasts and fashion-forward consumers. | Series F Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $195M | 2021-06-24 | [ LEAD ] |
SiMa.ai SiMa.ai scaling physical ai across across robotics, automotive, industrial automation, aerospace & defense, smart vision, and healthcare. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $80M | 2021-05-11 | [ PART ] |
Tanium Tanium is a unified endpoint management and security platform: agentic AI for real-time visibility, patching, and risk remediation across endpoints. | Sale of common stock Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2018-10-02 | [ PART ] |